NASDAQ
18.09.25 | 20:36
11,870 US-Dollar
+7,91 % +0,870
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 1 | Investing.com | ||
| 20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
| 08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat | 1 | Investing.com | ||
| 07.08. | Phathom Pharmaceuticals GAAP EPS of -$1.05 misses by $0.01, revenue of $39.5M beats by $3.92M | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 28.07. | Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 | 2 | GlobeNewswire (USA) | ||
| 23.06. | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 293 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| 19.06. | Phathom Q1 2025: VOQUEZNA-Akzeptanz steigt, Unternehmen strebt Profitabilität für 2026 an | 5 | Investing.com Deutsch | ||
| 16.06. | Phathom says FDA confirmed Voqueza exclusivity through May 2032 | 1 | Seeking Alpha | ||
| 16.06. | Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA | - | RTTNews | ||
| 16.06. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.06. | H.C. Wainwright maintains Buy on Phathom stock, $20 target | 3 | Investing.com | ||
| 09.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Phathom-Aktie mit Kursziel von 20 US-Dollar | 1 | Investing.com Deutsch | ||
| 09.06. | Goldman Sachs erhöht Kursziel für Phathom nach FDA-Exklusivitätsentscheidung | 4 | Investing.com Deutsch | ||
| 06.06. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.06. | Guggenheim bekräftigt Kaufempfehlung für Phathom-Aktie nach FDA-Exklusivitätszusage | 18 | Investing.com Deutsch | ||
| 06.06. | Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity | 6 | Investing.com | ||
| 06.06. | Stifel-Analysten bekräftigen Kaufempfehlung für Phathom Pharmaceuticals-Aktie | 4 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,950 | +5,98 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,395 | +6,72 % | BMO Capital bestätigt "Market Perform"-Rating für Sarepta-Aktie trotz Sorgen um Elevidys | ||
| IBIO | 0,700 | -2,78 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
| MYRIAD GENETICS | 6,500 | +4,00 % | Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now? | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| BIOXCEL THERAPEUTICS | 2,560 | +4,49 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,128 | +93,94 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,677 | +4,29 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| MACROGENICS | 1,381 | +6,39 % | MacroGenics stock initiated with Overweight rating by Barclays | ||
| SPERO THERAPEUTICS | 1,664 | +3,74 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| SCILEX | 25,390 | +1,72 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation | Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in... ► Artikel lesen | |
| INVIVYD | 1,250 | +7,76 % | Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer | NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's... ► Artikel lesen | |
| GENERATION BIO | 5,870 | 0,00 % | Generation Bio Co.: Generation Bio Announces 1-for-10 Reverse Stock Split | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,91 % bei einem Aktienkurs von 11,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.